Polygenicity of Comorbid Depression in Multiple Sclerosis.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
12
08
2022
accepted:
13
04
2023
medline:
2
8
2023
pubmed:
9
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Depression is common in multiple sclerosis (MS) and is associated with faster disability progression. The etiology of comorbid depression in MS remains poorly understood. Identification of individuals with a high risk of depression, through polygenic scores (PGS), may facilitate earlier identification. Previous genetic studies of depression considered depression as a primary disorder, not a comorbidity, and thus, findings may not generalize to MS. Body mass index (BMI) is a risk factor of both MS and depression, and its association may highlight differences in depression in MS. To improve the understanding of comorbid depression in MS, we will investigate PGS in people with MS, with the hypothesis that a higher depression PGS is associated with increased odds for comorbid depression in MS. Samples from 3 sources (Canada, UK Biobank, and the United States) were used. Individuals were grouped into cases (MS/comorbid depression) and compared with 3 control groups: MS/no depression, depression/no immune disease, and healthy persons. We used 3 depression definitions: lifetime clinical diagnoses, self-reported diagnoses, and depressive symptoms. The PGS were tested in association with depression using regression. A total of 106,682 individuals of European genetic ancestry were used: Canada (n = 370; 213 with MS), UK Biobank (n = 105,734; 1,390 with MS), and the United States (n = 578 with MS). Meta-analyses revealed individuals with MS and depression had a higher depression PGS compared with both individuals with MS without depression (odds ratio range per SD 1.29-1.38, A higher depression genetic burden was associated with approximately 30%-40% increased odds of depression in European genetic ancestry participants with MS compared with those without depression and was no different compared with those with depression and no comorbid immune disease. This study paves the way for further investigations into the possible use of PGS for assessing psychiatric disorder risk in MS and its application to non-European genetic ancestries.
Sections du résumé
BACKGROUND AND OBJECTIVES
Depression is common in multiple sclerosis (MS) and is associated with faster disability progression. The etiology of comorbid depression in MS remains poorly understood. Identification of individuals with a high risk of depression, through polygenic scores (PGS), may facilitate earlier identification. Previous genetic studies of depression considered depression as a primary disorder, not a comorbidity, and thus, findings may not generalize to MS. Body mass index (BMI) is a risk factor of both MS and depression, and its association may highlight differences in depression in MS. To improve the understanding of comorbid depression in MS, we will investigate PGS in people with MS, with the hypothesis that a higher depression PGS is associated with increased odds for comorbid depression in MS.
METHODS
Samples from 3 sources (Canada, UK Biobank, and the United States) were used. Individuals were grouped into cases (MS/comorbid depression) and compared with 3 control groups: MS/no depression, depression/no immune disease, and healthy persons. We used 3 depression definitions: lifetime clinical diagnoses, self-reported diagnoses, and depressive symptoms. The PGS were tested in association with depression using regression.
RESULTS
A total of 106,682 individuals of European genetic ancestry were used: Canada (n = 370; 213 with MS), UK Biobank (n = 105,734; 1,390 with MS), and the United States (n = 578 with MS). Meta-analyses revealed individuals with MS and depression had a higher depression PGS compared with both individuals with MS without depression (odds ratio range per SD 1.29-1.38,
DISCUSSION
A higher depression genetic burden was associated with approximately 30%-40% increased odds of depression in European genetic ancestry participants with MS compared with those without depression and was no different compared with those with depression and no comorbid immune disease. This study paves the way for further investigations into the possible use of PGS for assessing psychiatric disorder risk in MS and its application to non-European genetic ancestries.
Identifiants
pubmed: 37290970
pii: WNL.0000000000207457
doi: 10.1212/WNL.0000000000207457
pmc: PMC10401690
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e522-e532Subventions
Organisme : CIHR
ID : THC-135234
Pays : Canada
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Lancet. 2019 Mar 30;393(10178):1297
pubmed: 30938313
Mult Scler. 2022 Apr;28(5):730-741
pubmed: 34379023
Neurology. 2018 Apr 10;90(15):e1316-e1323
pubmed: 29523642
J Psychosom Res. 2017 Oct;101:17-23
pubmed: 28867419
Gen Hosp Psychiatry. 1987 Nov;9(6):426-34
pubmed: 3692149
Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72
pubmed: 29929117
Gen Hosp Psychiatry. 2022 Jul-Aug;77:21-28
pubmed: 35461162
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Nat Rev Genet. 2018 Sep;19(9):581-590
pubmed: 29789686
Mol Psychiatry. 2014 Sep;19(9):960-2
pubmed: 24492350
Nat Neurosci. 2021 Jul;24(7):954-963
pubmed: 34045744
Mult Scler. 2009 Mar;15(3):385-92
pubmed: 19153176
JAMA Psychiatry. 2021 Nov 1;78(11):1258-1269
pubmed: 34586374
Mult Scler Relat Disord. 2021 Jul;52:102982
pubmed: 34004436
Int J Epidemiol. 2019 Jun 1;48(3):834-848
pubmed: 30423117
Hum Mol Genet. 2018 Oct 15;27(20):3641-3649
pubmed: 30124842
Nutr Neurosci. 2016;19(2):79-85
pubmed: 25225836
Nat Rev Neurol. 2014 Sep;10(9):507-17
pubmed: 25112509
Biol Psychiatry Glob Open Sci. 2021 Jun;1(1):48-58
pubmed: 34278373
Mult Scler Relat Disord. 2020 Nov;46:102537
pubmed: 33296963
Nat Genet. 2018 May;50(5):668-681
pubmed: 29700475
Am J Psychiatry. 2019 May 1;176(5):376-387
pubmed: 30845820
Mult Scler. 2000 Apr;6(2):115-20
pubmed: 10773857
Genome Biol. 2018 Nov 14;19(1):179
pubmed: 30424772
JAMA Psychiatry. 2019 May 1;76(5):516-525
pubmed: 30698613
Neuroepidemiology. 2010 Aug;35(2):83-90
pubmed: 20551692
Neurology. 2022 Mar 1;98(9):e880-e892
pubmed: 35046135
Mol Psychiatry. 2022 Mar;27(3):1667-1675
pubmed: 34997191
Neurology. 2016 Apr 5;86(14):1279-1286
pubmed: 26962066
Nat Genet. 2019 Apr;51(4):584-591
pubmed: 30926966
Epidemiol Psychiatr Sci. 2019 Jun;28(3):333-342
pubmed: 29098977
Mult Scler. 2021 Nov;27(13):2077-2084
pubmed: 33591230
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Nat Neurosci. 2019 Mar;22(3):343-352
pubmed: 30718901
Brain. 2023 Feb 13;146(2):645-656
pubmed: 35253861
JMIR Res Protoc. 2018 Jan 17;7(1):e15
pubmed: 29343461
PLoS One. 2016 Sep 15;11(9):e0160261
pubmed: 27632167
Eur Neuropsychopharmacol. 2022 Feb;55:86-95
pubmed: 34844152
Int J MS Care. 2021 Jul-Aug;23(4):170-177
pubmed: 34483756
Epilepsy Behav. 2006 Dec;9(4):619-24
pubmed: 17049927
Transl Psychiatry. 2015 Jun 30;5:e592
pubmed: 26125155
Front Neurosci. 2022 Mar 08;16:827447
pubmed: 35350557
Mult Scler. 2021 Apr;27(4):603-612
pubmed: 32419624
Mult Scler Relat Disord. 2012 Apr;1(2):81-6
pubmed: 25876935
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JAMA Psychiatry. 2021 Oct 1;78(10):1152-1160
pubmed: 34379077